In oncology, for instance, genetic profiling of tumors enables the use of targeted therapies aimed at certain mutations, including HER2 inhibitors for breast cancer patients with HER2 overexpression (Oh and Bang, 2019). This evidence concerns the gene ERBB2 and breast carcinoma.